title: Clinical Experience with18F-Labeled Small Molecule Inhibitors of Prostate-Specific Membrane Antigen.
abstract: Prostate cancer (PCa) is the most common noncutaneous malignancy diagnosed in men. Despite the large number of men who will suffer from PCa at some point during their lives, conventional imaging modalities for this important disease (contrast-enhanced computed tomography, bone scan, and MR imaging) have provided only marginal to moderate success in appropriately guiding patient management in certain clinical contexts. In this review, the authors discuss radiofluorinated small molecule radiotracers that have been developed to bind to the transmembrane glycoprotein prostate-specific membrane antigen, a target that is nearly universally overexpressed on PCa epithelial cells.
authors.affiliation: The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: srowe8@jhmi.edu.
authors.forename: Steven P
authors.initials: SP
authors.lastname: Rowe
authors.affiliation: The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Gorin
authors.affiliation: The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
authors.forename: Roberto A
authors.initials: RA
authors.lastname: Salas Fragomeni
authors.affiliation: Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Drzezga
authors.affiliation: The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
authors.forename: Martin G
authors.initials: MG
authors.lastname: Pomper
mesh_terms: D000954:Antigens, Surface; D003545:Cysteine / Q000031:analogs & derivatives; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005462:Fluorine Radioisotopes; D043425:Glutamate Carboxypeptidase II / Q000037:antagonists & inhibitors*; D005977:Glutarates; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives; D008297:Male; D063065:Organophosphonates; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D014508:Urea / Q000031:analogs & derivatives
chemical_list: C572626:2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid; C000589485:2-fluoro-4-phosphonomethylpentanedioic acid; D000954:Antigens, Surface; D005462:Fluorine Radioisotopes; D005977:Glutarates; C530683:N-(N-((S)-1,3-Dicarboxypropyl)carbamoyl)-4-(18F)fluorobenzyl-L-cysteine; D063065:Organophosphonates; D019275:Radiopharmaceuticals; D014508:Urea; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II; D008239:Lysine; D003545:Cysteine
keywords: BAY 1075553; DCFBC; DCFPyL; Prostate cancer; Radiopharmaceutical